NeoGenomics Deferred Long Term Liab vs Net Invested Capital Analysis

NEO Stock

USD 17.73 0.01 0.06%

NeoGenomics financial indicator trend analysis is infinitely more than just investigating NeoGenomics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NeoGenomics is a good investment. Please check the relationship between NeoGenomics Deferred Long Term Liab and its Net Invested Capital accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.

Deferred Long Term Liab vs Net Invested Capital

Deferred Long Term Liab vs Net Invested Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NeoGenomics Deferred Long Term Liab account and Net Invested Capital. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between NeoGenomics' Deferred Long Term Liab and Net Invested Capital is 0.57. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Net Invested Capital in the same time period over historical financial statements of NeoGenomics, assuming nothing else is changed. The correlation between historical values of NeoGenomics' Deferred Long Term Liab and Net Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of NeoGenomics are associated (or correlated) with its Net Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Invested Capital has no effect on the direction of Deferred Long Term Liab i.e., NeoGenomics' Deferred Long Term Liab and Net Invested Capital go up and down completely randomly.

Correlation Coefficient

0.57

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Net Invested Capital

The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.

Most indicators from NeoGenomics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NeoGenomics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.At this time, NeoGenomics' Selling General Administrative is very stable compared to the past year. As of the 29th of November 2024, Sales General And Administrative To Revenue is likely to grow to 0.74, while Tax Provision is likely to drop (9.6 M).

	2021	2022	2023	2024 (projected)
Interest Expense	5.1M	1.5M	6.9M	7.3M
Depreciation And Amortization	62.1M	79.2M	72.6M	76.2M

Interest Expense Depreciation And Amortization

NeoGenomics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Total Current Assets	Common Stock	Property Plant And Equipment Net	Non Current Assets Total	Other Current Assets	Other Stockholder Equity	Property Plant And Equipment Gross	Property Plant Equipment	Short Long Term Debt Total	Current Deferred Revenue	Non Currrent Assets Other	Other Assets	Net Receivables
Total Assets		0.94	0.93	0.99	0.87	-0.69	0.3	0.96	0.98	-0.19	0.89	0.98	0.99	0.99	-0.19	0.99	1.0	0.97	0.96	0.98	0.93	0.98	0.78	-0.07	0.28	0.93
Other Current Liab	0.94		0.88	0.92	0.89	-0.76	0.1	0.88	0.9	-0.2	0.83	0.95	0.95	0.92	-0.2	0.93	0.95	0.91	0.89	0.95	0.86	0.95	0.69	-0.02	0.32	0.88
Total Current Liabilities	0.93	0.88		0.94	0.78	-0.68	0.51	0.88	0.86	-0.33	0.96	0.89	0.91	0.91	-0.33	0.93	0.94	0.86	0.87	0.89	0.86	0.89	0.72	0.01	0.33	0.98
Total Stockholder Equity	0.99	0.92	0.94		0.82	-0.63	0.35	0.96	0.98	-0.2	0.9	0.96	0.97	0.99	-0.2	1.0	0.99	0.96	0.96	0.96	0.94	0.96	0.81	-0.03	0.35	0.95
Net Debt	0.87	0.89	0.78	0.82		-0.76	0.05	0.74	0.8	-0.15	0.7	0.93	0.92	0.8	-0.15	0.81	0.9	0.82	0.81	0.9	0.78	0.93	0.56	-0.37	-0.08	0.74
Retained Earnings	-0.69	-0.76	-0.68	-0.63	-0.76		-0.03	-0.67	-0.61	0.17	-0.62	-0.75	-0.75	-0.63	0.17	-0.63	-0.71	-0.65	-0.7	-0.77	-0.45	-0.77	-0.39	0.25	0.09	-0.67
Accounts Payable	0.3	0.1	0.51	0.35	0.05	-0.03		0.27	0.22	-0.32	0.54	0.18	0.22	0.29	-0.32	0.32	0.3	0.21	0.29	0.18	0.3	0.19	0.26	0.08	0.2	0.53
Cash	0.96	0.88	0.88	0.96	0.74	-0.67	0.27		0.98	-0.16	0.85	0.94	0.94	0.98	-0.16	0.97	0.94	0.97	0.97	0.96	0.88	0.94	0.77	0.07	0.37	0.9
Cash And Short Term Investments	0.98	0.9	0.86	0.98	0.8	-0.61	0.22	0.98		-0.15	0.83	0.96	0.96	0.99	-0.15	0.98	0.96	0.99	0.97	0.97	0.92	0.96	0.79	-0.03	0.35	0.87
Common Stock Total Equity	-0.19	-0.2	-0.33	-0.2	-0.15	0.17	-0.32	-0.16	-0.15		-0.52	-0.16	-0.18	-0.19	1.0	-0.2	-0.19	-0.19	-0.17	-0.16	-0.21	-0.17	0.23	-0.03	-0.08	-0.31
Common Stock Shares Outstanding	0.89	0.83	0.96	0.9	0.7	-0.62	0.54	0.85	0.83	-0.52		0.83	0.86	0.88	-0.52	0.9	0.89	0.84	0.84	0.84	0.83	0.84	0.63	0.03	0.36	0.97
Non Current Liabilities Total	0.98	0.95	0.89	0.96	0.93	-0.75	0.18	0.94	0.96	-0.16	0.83		1.0	0.96	-0.16	0.96	0.99	0.97	0.96	1.0	0.9	1.0	0.73	-0.16	0.16	0.88
Total Liab	0.99	0.95	0.91	0.97	0.92	-0.75	0.22	0.94	0.96	-0.18	0.86	1.0		0.97	-0.18	0.96	0.99	0.97	0.96	1.0	0.91	1.0	0.73	-0.14	0.18	0.9
Total Current Assets	0.99	0.92	0.91	0.99	0.8	-0.63	0.29	0.98	0.99	-0.19	0.88	0.96	0.97		-0.19	0.99	0.97	0.98	0.97	0.97	0.93	0.96	0.79	-0.01	0.37	0.92
Common Stock	-0.19	-0.2	-0.33	-0.2	-0.15	0.17	-0.32	-0.16	-0.15	1.0	-0.52	-0.16	-0.18	-0.19		-0.2	-0.19	-0.19	-0.17	-0.16	-0.21	-0.17	0.23	-0.03	-0.08	-0.31
Property Plant And Equipment Net	0.99	0.93	0.93	1.0	0.81	-0.63	0.32	0.97	0.98	-0.2	0.9	0.96	0.96	0.99	-0.2		0.98	0.97	0.95	0.96	0.93	0.96	0.81	-0.01	0.4	0.94
Non Current Assets Total	1.0	0.95	0.94	0.99	0.9	-0.71	0.3	0.94	0.96	-0.19	0.89	0.99	0.99	0.97	-0.19	0.98		0.96	0.95	0.98	0.93	0.99	0.77	-0.11	0.22	0.93
Other Current Assets	0.97	0.91	0.86	0.96	0.82	-0.65	0.21	0.97	0.99	-0.19	0.84	0.97	0.97	0.98	-0.19	0.97	0.96		0.98	0.97	0.92	0.97	0.7	0.0	0.3	0.87
Other Stockholder Equity	0.96	0.89	0.87	0.96	0.81	-0.7	0.29	0.97	0.97	-0.17	0.84	0.96	0.96	0.97	-0.17	0.95	0.95	0.98		0.96	0.86	0.96	0.7	-0.07	0.29	0.88
Property Plant And Equipment Gross	0.98	0.95	0.89	0.96	0.9	-0.77	0.18	0.96	0.97	-0.16	0.84	1.0	1.0	0.97	-0.16	0.96	0.98	0.97	0.96		0.89	1.0	0.74	-0.13	0.19	0.89
Property Plant Equipment	0.93	0.86	0.86	0.94	0.78	-0.45	0.3	0.88	0.92	-0.21	0.83	0.9	0.91	0.93	-0.21	0.93	0.93	0.92	0.86	0.89		0.89	0.73	0.11	0.28	0.86
Short Long Term Debt Total	0.98	0.95	0.89	0.96	0.93	-0.77	0.19	0.94	0.96	-0.17	0.84	1.0	1.0	0.96	-0.17	0.96	0.99	0.97	0.96	1.0	0.89		0.72	-0.15	0.16	0.88
Current Deferred Revenue	0.78	0.69	0.72	0.81	0.56	-0.39	0.26	0.77	0.79	0.23	0.63	0.73	0.73	0.79	0.23	0.81	0.77	0.7	0.7	0.74	0.73	0.72		-0.02	0.41	0.75
Non Currrent Assets Other	-0.07	-0.02	0.01	-0.03	-0.37	0.25	0.08	0.07	-0.03	-0.03	0.03	-0.16	-0.14	-0.01	-0.03	-0.01	-0.11	0.0	-0.07	-0.13	0.11	-0.15	-0.02		0.53	0.05
Other Assets	0.28	0.32	0.33	0.35	-0.08	0.09	0.2	0.37	0.35	-0.08	0.36	0.16	0.18	0.37	-0.08	0.4	0.22	0.3	0.29	0.19	0.28	0.16	0.41	0.53		0.38
Net Receivables	0.93	0.88	0.98	0.95	0.74	-0.67	0.53	0.9	0.87	-0.31	0.97	0.88	0.9	0.92	-0.31	0.94	0.93	0.87	0.88	0.89	0.86	0.88	0.75	0.05	0.38

Click cells to compare fundamentals

NeoGenomics Account Relationship Matchups

NeoGenomics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	709.5M	988.3M	1.9B	1.7B	1.7B	1.8B
Other Current Liab	(1.6M)	39.2M	56.1M	55.2M	62.6M	65.8M
Total Current Liabilities	63.9M	73.2M	87.2M	89.9M	96.3M	101.1M
Total Stockholder Equity	507.4M	694.3M	1.1B	998.0M	941.5M	988.6M
Net Debt	(40.1M)	(10.5M)	296.0M	347.7M	269.2M	282.7M
Retained Earnings	(11.4M)	(7.2M)	(14.8M)	(159.1M)	(247.1M)	(234.7M)
Accounts Payable	50.1M	25.0M	17.9M	20.5M	20.3M	11.8M
Cash	173.0M	228.7M	316.8M	263.2M	342.5M	359.6M
Cash And Short Term Investments	173.0M	296.3M	515.4M	438.0M	415.2M	436.0M
Common Stock Total Equity	105K	112K	124K	127K	114.3K	102.7K
Common Stock Shares Outstanding	103.6M	111.8M	120.0M	124.2M	125.5M	131.8M
Liabilities And Stockholders Equity	709.5M	988.3M	1.9B	1.7B	1.7B	1.8B
Non Current Liabilities Total	138.2M	220.9M	674.3M	652.1M	643.4M	675.6M
Total Liab	202.1M	294.0M	761.5M	742.0M	739.7M	776.7M
Total Current Assets	290.7M	448.7M	681.5M	605.3M	596.8M	626.7M
Common Stock	105K	112K	124K	127K	114.3K	102.7K
Property Plant And Equipment Net	90.7M	151.9M	211.7M	198.6M	183.8M	193.0M
Non Current Assets Total	418.8M	539.6M	1.2B	1.1B	1.1B	1.1B
Other Current Assets	9.1M	16.1M	30.6M	23.3M	26.2M	27.5M
Other Stockholder Equity	520.3M	701.4M	1.1B	1.2B	1.2B	1.2B
Property Plant And Equipment Gross	90.7M	131.7M	321.6M	330.5M	342.0M	359.1M
Accumulated Other Comprehensive Income	(1.6M)	10K	(638K)	(3.9M)	(1.7M)	(1.8M)
Property Plant Equipment	64.2M	85.9M	211.7M	102.5M	117.9M	123.8M
Short Long Term Debt Total	132.9M	218.2M	612.8M	610.9M	611.7M	642.3M
Current Deferred Revenue	1.6M	4.0M	5.2M	7.6M	2.1M	2.2M
Non Currrent Assets Other	2.8M	21.0M	7.2M	(29.7M)	4.7M	5.0M
Other Assets	2.8M	54.4M	7.2M	5.1M	5.9M	3.8M
Net Receivables	94.2M	106.8M	112.1M	119.7M	131.2M	137.8M
Inventory	14.4M	29.5M	23.4M	24.3M	24.2M	25.4M
Short Term Debt	13.8M	7.8M	8.0M	6.7M	11.2M	8.0M
Long Term Debt	91.8M	168.1M	532.5M	535.3M	538.2M	565.1M
Other Liab	17.1M	10.4M	69.5M	47.8M	55.0M	57.7M
Net Tangible Assets	182.2M	362.6M	138.8M	67.0M	77.0M	70.4M
Good Will	198.6M	211.1M	527.1M	522.8M	601.2M	631.2M
Retained Earnings Total Equity	(11.4M)	(7.2M)	(14.8M)	(159.1M)	(143.2M)	(136.0M)
Long Term Debt Total	115.9M	168.1M	532.5M	535.3M	615.6M	646.4M
Capital Surpluse	520.3M	701.4M	1.1B	1.2B	1.3B	1.4B
Capital Lease Obligations	24.0M	50.1M	80.3M	75.6M	73.5M	77.2M
Deferred Long Term Liab	15.6M	5.4M	55.5M	34.8M	40.0M	42.0M

Pair Trading with NeoGenomics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeoGenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeoGenomics will appreciate offsetting losses from the drop in the long position's value.

Moving against NeoGenomics Stock

0.47	EQ	Equillium	Pair Corr
0.34	DOMH	Dominari Holdings	Pair Corr

The ability to find closely correlated positions to NeoGenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeoGenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeoGenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeoGenomics to buy it.

The correlation of NeoGenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeoGenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeoGenomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for NeoGenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether NeoGenomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeoGenomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neogenomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neogenomics Stock:

How To Invest In NeoGenomics

Details

Is NeoGenomics Stock a good investment?

Details

What is NeoGenomics' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.

You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

1.306

Earnings Share

(0.61)

Revenue Per Share

5.098

Quarterly Revenue Growth

0.104

Return On Assets

(0.03)

The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NeoGenomics Deferred Long Term Liab vs Net Invested Capital Analysis

Deferred Long Term Liab vs Net Invested Capital

Deferred Long Term Liab vs Net Invested Capital Correlation Analysis

Correlation Coefficient

Deferred Long Term Liab

Net Invested Capital

NeoGenomics fundamental ratios Correlations

NeoGenomics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NeoGenomics fundamental ratios Accounts

Pair Trading with NeoGenomics

Moving against NeoGenomics Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Total Assets
Property Plant And Equipment Net	+ 1.0	Total Stockholder Equity
Common Stock	+ 1.0	Common Stock Total Equity
Total Liab	+ 1.0	Non Current Liabilities Total
Property Plant And Equipment Gross	+ 1.0	Non Current Liabilities Total
Short Long Term Debt Total	+ 1.0	Non Current Liabilities Total

Short Long Term Debt Total	- 0.77	Retained Earnings
Property Plant And Equipment Gross	- 0.77	Retained Earnings
Retained Earnings	- 0.76	Net Debt
Retained Earnings	- 0.76	Other Current Liab
Total Liab	- 0.75	Retained Earnings
Non Current Liabilities Total	- 0.75	Retained Earnings